enGene (NASDAQ:ENGN) Shares Gap Down to $15.74

Shares of enGene Holdings Inc. (NASDAQ:ENGN) gapped down prior to trading on Thursday . The stock had previously closed at $15.74, but opened at $15.34. enGene shares last traded at $15.34, with a volume of 1,122 shares.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Leerink Partnrs reaffirmed an “outperform” rating on shares of enGene in a research report on Tuesday, February 20th. UBS Group began coverage on enGene in a research note on Thursday, March 28th. They issued a “buy” rating and a $37.00 price objective for the company. Guggenheim started coverage on enGene in a research note on Monday. They set a “buy” rating and a $34.00 target price on the stock. SVB Leerink began coverage on enGene in a research report on Tuesday, February 20th. They issued an “outperform” rating and a $31.00 target price for the company. Finally, Morgan Stanley initiated coverage on shares of enGene in a research report on Friday, March 8th. They set an “overweight” rating and a $40.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, enGene currently has a consensus rating of “Buy” and an average target price of $35.50.

enGene Stock Down 4.7 %

The stock’s fifty day simple moving average is $15.71.

Hedge Funds Weigh In On enGene

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC purchased a new position in enGene in the fourth quarter worth approximately $185,000. Goldman Sachs Group Inc. acquired a new stake in shares of enGene in the 4th quarter valued at $346,000. Royal Bank of Canada purchased a new stake in shares of enGene during the 4th quarter worth $349,000. Vivo Capital LLC acquired a new position in shares of enGene during the fourth quarter worth $6,264,000. Finally, Omega Fund Management LLC purchased a new position in enGene in the fourth quarter valued at $10,441,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.